Analyst Perspectives | Cautious optimism surrounds Adverum, with price targets ranging from $4 to $33, reflecting the high-risk, high-reward nature of its gene therapy endeavors |
Market Opportunity | Explore the substantial growth potential in the wet AMD treatment market, where Adverum's one-time gene therapy could revolutionize patient care and capture significant market share |
Financial Tightrope | With $83 million in cash reserves, Adverum faces financial challenges as it progresses through costly clinical trials, potentially necessitating strategic funding decisions |
Gene Therapy Frontie | Adverum Biotechnologies leads in ocular gene therapy development, with pivotal studies for wet AMD underway and global expansion plans on the horizon |
Metrics to compare | ADVM | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipADVMPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −1.4x | −0.4x | |
PEG Ratio | 0.00 | −0.03 | 0.00 | |
Price / Book | 0.0x | 3.1x | 2.6x | |
Price / LTM Sales | 0.0x | 9.6x | 3.0x | |
Upside (Analyst Target) | 0.0% | 90.8% | 51.9% | |
Fair Value Upside | Unlock | −2.9% | 7.2% | Unlock |